Date: Oct 16, 2014 Author: http://www.ptipep.com/story-peptide-mimics-as-a-drug-target-for-ebola-university-of-utah-researchers Source: Company Data (
click here to go to the source)
TUCSON, Ariz.--(BUSINESS WIRE)--Protein Technologies, a leader in the field of peptide synthesis instrumentation, today announces that researchers at the University of Utah have developed an innovative use of peptide mimics as drug target surrogates to develop new treatments for Ebola. A large collaborative team led by Debra Eckert, Ph.D., research assistant professor of biochemistry, and Michael S. Kay, M.D., Ph.D., professor of biochemistry, have identified a peptide sequence that is conserved in all known species of Ebola and is thought to control the virus' entry into human cells. This peptide mimic can be used as a target to identify new drug treatments to control the Ebola virus.
"The use of peptide mimics as drug targets played a key role in the development of treatments for HIV, and we believe this approach can be applied to the treatment of Ebola," said Dr. Kay. "The Prelude™ system from Protein Technologies enabled us to quickly design and optimize the synthesis of the peptide mimics of the ebolavirus N-trimer."
"The research being performed in Dr. Kay's laboratory on the Prelude parallel peptide synthesizer has broad implications for treating individuals affected by the Ebola virus," said Nate Cosper, Ph.D., President and CEO of Protein Technologies. "Many of our collaborators and partners are developing peptides for use as therapeutic treatments, and we are encouraged by this use of a peptide mimic as a drug discovery tool."
The Prelude is a six-channel, parallel peptide synthesizer that has been designed to facilitate incorporation of proprietary or unusual monomers, which makes it easier for researchers to prepare long or difficult peptides and peptide mimics.
For additional information about this research, please visit http://onlinelibrary.wiley.com/doi/10.1002/pro.2578/abstract.
About Protein Technologies, Inc.
Protein Technologies, Inc. is a leading supplier of quality peptide synthesizers and reagents to universities, biotechnology companies, and pharmaceutical companies. We have built our company on the belief that our products must be the highest possible quality, and we support our products with a dedicated field service team. We are proud of our reputation for reliability and value the trust our customers and partners have placed in PTI. Today we continue to grow and innovate to serve the needs of the peptide synthesis community. To learn more about Protein Technologies, please visit www.ptipep.com.
Prelude is a trademark of Protein Technologies, Inc.
Contacts
Protein Technologies, Inc.
Nate Cosper, Ph.D., 520-629-9626
President & CEO
info@ptipep.com
